Story thread · 4 reports / 4 sources

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

biopharmadive.com · 11dShare

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

First report: Sanofi beats Q2 growth expectations on Dupixent sales surge — seekingalpha.com, 12d